Last reviewed · How we verify
Farma de Colombia SA — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| GROUP C: Chlorthalidone | GROUP C: Chlorthalidone | phase 3 | Thiazide-like diuretic | Sodium-chloride cotransporter (NCC) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Eurofarma Laboratorios S.A. · 1 shared drug class
- Hospices Civils de Lyon · 1 shared drug class
- NHS Greater Glasgow and Clyde · 1 shared drug class
- University of North Carolina, Chapel Hill · 1 shared drug class
- University of Virginia · 1 shared drug class
- VA Office of Research and Development · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Farma de Colombia SA:
- Farma de Colombia SA pipeline updates — RSS
- Farma de Colombia SA pipeline updates — Atom
- Farma de Colombia SA pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Farma de Colombia SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/farma-de-colombia-sa. Accessed 2026-05-17.